Screener
Kura Oncology KURA EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Kura Oncology’s reported figures.
The source filing: Kura Oncology’s 10-Q, filed May 12, 2026. Open the filing →
- Filed
- May 12, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219481
FAQ
- What is Kura Oncology's EBITDA?
- Kura Oncology (KURA) reported EBITDA of -$78.46M in Q1 2026.
- How has Kura Oncology's EBITDA changed year-over-year?
- Kura Oncology's EBITDA decreased by 21.7% year-over-year, from -$64.46M to -$78.46M.
- What is the long-term trend for Kura Oncology's EBITDA?
- Over 3 years (2022 to 2025), Kura Oncology's EBITDA has grown at a 29.6% compound annual growth rate (CAGR), from -$139.11M to -$302.6M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Kura Oncology's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude